Importantly, this study declaimed that IGF2BP3 might participate in immune modulation processes, by interacting with immune infiltration (especially myeloid dendritic cell) and immune checkpoints (PDCD1 and HAVCR2) in HCC patients. The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.